D. E. Shaw & Co., Inc. Immuneering Corp Transaction History
D. E. Shaw & Co., Inc.
- $107 Billion
- Q3 2024
Shares
2 transactions
Others Institutions Holding IMRX
# of Institutions
41Shares Held
4.64MCall Options Held
0Put Options Held
0-
Vanguard Group Inc Valley Forge, PA1.07MShares$2.34 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD810KShares$1.77 Million0.0% of portfolio
-
Black Rock Inc. New York, NY533KShares$1.17 Million0.0% of portfolio
-
Morgan Stanley New York, NY449KShares$983,9910.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny246KShares$539,3310.0% of portfolio
About Immuneering Corp
- Ticker IMRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,392,300
- Market Cap $57.8M
- Description
- Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to tr...